The trajectory of Sildenafil presents a nuanced case for observers in the drug sector. While initially a tremendous success, creating vast sums, the patent end and the subsequent entry of generic versions have significantly impacted revenue. This raises questions about the future profitability of related drug developments and suggests that simply e